Effects of ZNF139 on gastric cancer cells and mice with gastric tumors.

Gastric cancer (GC) is the fourth most common type of cancer, worldwide. The major molecular factors associated with the pathogenesis of GC remain unclear. Previous studies found that zinc finger proteins are highly abundant in human eukaryotes and tissues, and play an important role in maintaining normal cellular functions and have an association with tumor initiation. In the current study, interference technology was used to silence the ZNF139 protein, a zinc finger protein that was previously found to be closely associated with GC. The results showed that cell viability and proliferation were inhibited in the Znf139-knockdown of GC cells. Additional study found that the expression levels of B cell lymphoma-2 (Bcl-2) and survivin messenger RNAs and proteins were downregulated in Znf139-silenced cells, indicating that cells expression Znf139 are able to induce the growth of tumor cells by mediating the apoptosis pathway. Further in vivo experiments showed that Znf139 knockdown downregulated the expression levels of Bcl-2 and survivin in mice. Overall, the in vitro and in vivo findings of the present study indicate that ZNF139 may be actively involved in the progression of GC.

Introduction

Gastric cancer (GC) is the fourth most common type of cancer and ranks as the second most common cause of cancer-associated mortalities, while the incidence rate is gradually rising every year worldwide (1). Although certain advances, such as combination chemotherapy, have been achieved in chemotherapy in recent years, the therapeutic effect remains unsatisfactory (2). Numerous molecular factors associated with pathogenesis of GC have been reported, but the key factors remain unclear. Therefore, finding out the controlling factors of GC and their effects on its pathogenesis may increase the current understanding of the mechanisms underlying gastric carcinogenesis and facilitate the development gene-based therapies.

Zinc finger proteins are highly abundant in human eukaryotic cells and tissues and are important for the maintenance of normal cellular functions (3). As previously reported, numerous members of the zinc finger protein family are associated with the initiation, development, invasion and metastasis of tumors, including ZNF165 in urinary bladder cancer and ZNF217 in colorectal adenoma and ovarian cancer (4,5). ZNF139, a member of the kruppel family of zinc-finger-containing transcription factors, was found to be closely associated with GC in a previous study (6). However, the mechanism of ZNF139 in the growth and metastasis of GC cells was not clarified. Therefore, the aim of the present study is to detect the specific impact and the mechanism of ZNF139 on GC tumor cells by using interference technology, orthotopic transplantation and immunohistochemistry.

Materials and methods

Cell culture

The human GC SGC7901 cell line was purchased from The Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China) and were cultivated in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), penicillin (100 unit/ml) and streptomycin (100 µg/ml). The tumor cells were cultured in a humidified atmosphere of 5% CO2 at 37°C.

Plasmid construction and transfection

The vector RNAi-Ready pSIREN-RetroQ-ZsGreen plasmid was obtained from Clontech Laboratories, Inc. (Mountainview, CA, USA). The expression vectors containing either the anti-Znf139 small interfering RNA (siRNA) sequence ACCTCGGAAGATTCAGCAT for the negative control (scramble) sequence GACGAGTTGACTGCGATTG were constructed, as previously described (7), and termed Znf139-siRNA or siRNA-scramble expression vector, respectively. Znf139-siRNA expression vector (Znf139-siRNA group), siRNA-scramble expression vector (siRNA-scramble group) or blank expression vector (mock group) were transfected into SGC7901 cells using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. A fluorescence microscope was used to observe the transfection efficiency at 24 h after transfection and 80% transfection efficiency was considered to be successful transfection. Transfection efficiency was calculated as follows: Transfection efficiency (%) =(number of fluorescent cells/total number of cells) × 100.

3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay

SGC7901 cells (1×104 per well) were planted into 96-well microtiter plates and incubated overnight prior to being transfected with siRNA. At 24 h subsequent to transfection, 20 µl MTT (Sigma-Aldrich, St. Louis, MO, USA) assay solution (5 mg/ml) was added into the wells for 4 h at 37°C. After discarding the medium, the formazan crystals were dissolved in dimethyl sulfoxide (DMSO) and the absorbance was measured at 490 nm on a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

5-ethynyl-2′-deoxyuridine (EdU) assay

Briefly, cells (1×104 cells per well) were seeded into 96-well plates with 100 µl EdU (50 µM; Sigma-Aldrich) added, and cultured in an incubator for 2 h at room temperature. The cells were fixed with 4% paraformaldehyde for 30 min, treated with glycine (2 mg/ml) for 5 min and washed with phosphate-buffered saline (PBS) three times. Subsequently, 100 µl 1X Apollo® reaction cocktail (Sigma-Aldrich) was added to the cells to react for 30 min in the dark, and 1X Hoechst 33342 (Sigma-Aldrich) was used to stain cell nuclei for 30 min at room temperature. The nuclear morphology was then observed with an immunofluorescence microscope and the percentage of EdU-labeled (red) cells was noted.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted from SGC7901 cells using Trizol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer's protocol. RNA (2 µg) was then reverse transcribed into complementary DNA (cDNA) using the SuperScript Reverse transcriptase kit (Invitrogen; Thermo Fisher Scientific, Inc.). RT-qPCR was performed with the SYBR Premix Ex Taq II (Takara Bio, Inc., Otsu, Japan) on an ABI-7500 Sequence Detection System (Applied Biosystems; Thermo Fisher Scientific, Inc.). Housekeeping gene β-actin was chosen as an internal control to detect the relative expression of the target genes. The thermal cycling conditions were 95°C for 30 sec and 58°C for 1 min. The sequences of the PCR primers were as follows: Znf139 forward, CTTCCTGAGTTCTTGGTTTCG and reverse, CCTTTGACCCACTGGTTTATG; Bcl-2 forward, GGTGGGGTCATGTGTGTGG and reverse, CGGTTCAGGTACTCAGTCATCC; survivin forward, GGACCGCCTAAGAGGGCGTGC and reverse, AATGTAGAGATGCGGTGGTCCTT; β-actin forward, CATGTACGTTGCTATCCAGGC and reverse, CTCCTTAATGTCACGCACGAT. The comparative quantification (Cq) cycle method (2−ΔΔCq) was used to calculate relative expression levels of Znf139/β-actin, Bcl-2/β-actin and survivin/β-actin (8).

Western blot analysis

The cells were lysed using a ReadyPrep Protein Extraction kit (Bio-Rad Laboratories, Inc.) for 5 min. After removing cell debris by centrifugation at 12,000 × g for 15 min, the supernatant containing the proteins was collected and boiled in sample buffer for 5 min. The concentrated proteins were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis so that the specific proteins could be transferred onto polyvinylidene fluoride membranes (Roche Diagnostics, Basel, Switzerland). The membranes were blocked using PBS containing 0.05% Tween 20 and 5% skim milk for 1 h at room temperature. After being washed 3 times in Tris-buffered saline containing Tween 20, the membranes were incubated with rabbit anti-mouse ZNF139 polyclonal (1:800 dilution; cat no. ab126124; Abcam, Cambridge, UK), Bcl-2 monoclonal (1:800 dilution; cat no. ab32124; Abcam), survivin polyclonal (1:800 dilution; cat no. ab469; Abcam) or β-actin polyclonal (1:5,000 dilution; cat no. ab8227; Abcam) primary antibodies overnight at 4°C, and then exposed to goat anti-rabbit horseradish peroxidase-conjugated secondary antibody (1:5,000 dilution; cat no. 074-1506; KPL, Inc., Gaithersburg, MD, USA). Immunoreactive bands were detected by the enhanced chemiluminescence system (GE Healthcare Life Sciences, Little Chalfont, UK).

Mouse model establishment

Establishment of the GC tissue orthotopic transplantation mouse model was separated into 2 steps. Firstly, subcutaneous tumor-transplanted mouse model was established using 6–8 weeks old male BALB/C (nu/nu) nude mice. All mice were acclimated to a natural day-night cycle at 21°C, and given free access to food and water for 1 week prior to the trial. These nude mice were divided into 2 groups: Group A was injected with Znf139-knockdown SGC7901 cells and group B was injected with SGC7901 cells transfected with siRNA-scramble. After the mice were subcutaneously injected with 7×104 cells per mouse on the backside, the mice were kept in specific pathogen free conditions for 3 weeks until the implanted tumor grew to 1 cm diameter. The mice were anesthetized with 6% pentobarbital sodium and sacrificed by cervical dislocation. Then the tumor tissues were removed, sliced into 1×1×1 mm pieces and implanted to the backside of other nude mice. The source of the orthotopic transplantation was coming from the sixth generation subcutaneously-transplanted tumor slices. For the second step, the establishment of the orthotopic transplanted mouse model, nude mice were anesthetized with 6% pentobarbital sodium. A 5–10 mm abdominal incision was made along the left paramedian line in order to expose the gastric wall. The serosa of the greater curvature of stomach was cut so that the tumor slice could be implanted. OB glue (1–2 drops; Guangzhou Baiyun Medical Adhesive Co., Ltd., Baiyun, China) was used to seal the rupture and the enterocoelia was closed using a suture. Mice were weighed daily. After 90 days, all mice were sacrificed by cervical dislocation due to the development of systemic failure, and the tumors excised from stomach were measured using a vernier caliper and analytical balance. The procedures for the care and use of animals were approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University (Shijiazhuang, Hebei) and all applicable institutional and governmental regulations concerning the ethical use of animals were followed.

Statistical analysis

Statistical analysis was performed using SPSS software (version 17.0; SPSS Inc., Chicago, IL, USA). Data were analyzed by one-way analysis of variance and are expressed as the mean ± standard deviation. All experiments were repeated three times. Multiple comparison between the groups was performed using the Student-Newman-Keuls method. P<0.05 was considered to indicate a statistically significant difference.

Results

Effect of siRNA on Znf139 expression in SGC7901 cells

To demonstrate the role of ZNF139 on tumor growth and apoptosis, a ZNF139 RNA interference vector was constructed with green fluorescent protein transfected into the GC SGC7901 cell line. In the cells transfected with Znf139-siRNA, the expression of ZNF139 was evidently decreased in the messenger RNA (mRNA) (Fig. 1A) and protein (Fig. 1B) compared with the siRNA-scramble and mock control groups (all P=0.001). There was no significant difference between the siRNA-scramble and mock control groups (Fig. 1). These results indicated that the constructed Znf139-siRNA expression vector was able to inhibit the transcription and translation of endogenous Znf139 efficiently.

Figure 1.

Expression of ZNF139 mRNA and protein levels in the gastric cancer SGC7901 cell line subjected to Znf139-siRNA. Cells were transfected with 100 nM Znf139-siRNA for 48 h and the expression of ZNF139 was identified by (A) reverse transcription-quantitative polymerase chain and (B) western blot analysis. The expression of ZNF139 was significantly increased in Znf139-siRNA cells versus cells in the mock and siRNA-scramble group. **P<0.01 vs. siRNA-ZNF139. ZNF139, zinc finger protein 139; mRNA, messenger RNA; siRNA, small interefering RNA.

Effect of Znf139-siRNA on cell growth

Further experiments were performed to detect the effect of ZNF139 on cell growth. SGC7901 cells were transfected with Znf139-siRNA and siRNA-scramble. As shown in Fig. 2, the growth of Znf139-knockdown cells was inhibited significantly after 48 h transfection (Fig. 2A). Subsequently, EdU and MTT assays were used to confirm whether cell viability and proliferation were inhibited following the knockdown of Znf139. According to the EdU analysis, the proliferation of the Znf139-knockdown cells was evidently inhibited compared with the siRNA-scramble and mock control groups (Fig. 2B). As shown in the MTT assay, the viability of Znf139-silenced cells was evidently inferior compared with the siRNA-scramble and mock control groups (P=0.001 and P=0.003, respectively; Fig. 2C). These results suggest the Znf139 gene is associated with the growth and proliferation of gastric tumor cells.

Figure 2.

Effect of Znf139 on SGC7901 cell growth. SGC7901 cells were transfected with 100 nM Znf139-siRNA for 48 h. (A) Growth activity of SGC7901 cells was significantly inhibited in the cells transfected with Znf139-siRNA compared with the negative and the blank groups. (B) 5-ethynyl-2′-deoxyuridine and (C) 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assays were performed to test the effect of Znf139 on cell growth. Cell growth was significantly decreased in Znf139-siRNA cells versus cells in the mock and siRNA-scramble group **P<0.01 vs. siRNA-ZNF139. siRNA, small interefering RNA; ZNF139, zinc finger protein 139; OD, optical density.

Effect of Znf139-siRNA on cell apoptosis

To further investigate the association between ZNF139 and cell apoptosis, the Bcl-2 and survivin genes were detected with qPCR and western blot analysis. The results showed that the expression levels of Bcl-2 and survivin mRNAs (P=0.001 and P=0.002, respectively) and proteins were downregulated in Znf139-silenced cells compared with the siRNA-scramble and mock groups (Fig. 3). These data indicated that Znf139 was able to induce the growth of tumor cells by mediating the apoptosis pathway.

Figure 3.

Effect of Znf139 on the expression of Bcl-2 and survivin in SGC7901 cells. Cells were transfected with Znf139-siRNA or control scramble-siRNA. The mRNA expression levels of (A) Bcl-2 and (B) survivin were detected by reverse transcription-quantitative polymerase chain reaction and the (C) Bcl-2 and survivin protein levels were detected by western blot analysis. The expression levels of Bcl-2 and survivin were significantly decreased in Znf139-siRNA cells versus cells in the mock and siRNA-scramble group. **P<0.01 vs. siRNA-ZNF139. ZNF139, zinc finger protein 139; siRNA, small interfering RNA; mRNA, messenger RNA; Bcl-2, B-cell lymphoma-2.

Znf139 knockdown downregulated the expression of Bcl-2 and survivin in mice

Through weighing the mice daily, after the establishment of the human GC nude mouse orthotopic transplantation model, the mice appeared to experience systemic failure, showing symptoms of emaciation, roachback, listlessness and hypoactivity by 90 days. The mice were then sacrificed by cervical dislocation and the tumors excised from stomach were measured using a vernier caliper and analytical balance. The tumors in mice orthotopically transplanted with Znf139-knockdown SGC7901 cells were significantly inhibited compared with those orthotopically transplanted with siRNA-scramble SGC7901 cells, and there was no metastasis of the tumor in peritoneum and lymph node in mice orthotopically transplanted with Znf139-knockdown SGC7901 cells. The western blot analysis results revealed that the expression levels of Bcl-2 and survivin were significantly decreased in the tumors of orthotopic transplant mice that interfered with Znf139 siRNA (Fig. 4), which was in agreement with the results of the in vitro experiment.

Figure 4.

Effects of silencing ZNF139 on the expression of Bcl-2 and survivin in mouse models. The expression of ZNF139 was markedly inhibited in Znf139-siRNA cells compared with cells in siRNA-scramble group, and the expression levels of Bcl-2 and survivin were significantly decreased in Znf139-siRNA cells compared with cells in the siRNA-scramble group. ZNF139, zinc finger protein 139; Bcl-2, B-cell lymphoma-2.

Discussion

GC is one of the most common digestive system malignant tumors worldwide, which is associated with a high fatality rate, particularly in Asia. Therefore, researching the mechanism of GC is of great importance (9). Various molecular factors have been be shown to be associated with the pathogenesis of GC, but the major genes affecting the growth and prognosis of GC tumors remains unclear. The GC SGC7901 cell lines were moderately differentiated adenocarcinoma cells, which are commonly found in clinical patients (10). ZNF139, a member of the zinc finger protein family, is a regulating factor at transcription level (6). Dekken et al first discovered the increased expression of ZNF139 in an adenocarcinoma of the esophago-gastric junction (11). A previous study found that ZNF139 could affect gastric tumors by promoting the expression of fascin and heterogeneous nuclear ribonucleoproteins A2/B1 (12). In addition, the expression of ZNF139 was found to be closely associated with GC, indicating that ZNF139 may be involved in gastric carcinogenesis and development (12). Another previous study showed that ZNF139 was involved in GC multidrug resistance by simultaneously promoting the expression of multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 1 (MRP1) and Bcl-2, and inhibiting Bcl-2-associated X protein (13). In order to explore the association between ZNF139 and the growth of tumor cells, the expression of ZNF139 was silenced in SGC7901 cells by first applying RNA interference technology. As shown in the results, the viability and proliferation were extremely suppressed in the SGC7901 cells with Znf139 knockdown, indicating that the inhibition of ZNF139 was conducive to the growth of GC cells in vitro.

To investigate the influence of ZNF139 in vivo, a human GC nude mouse orthotopic transplantation model was created, which could simulate GC biological behavior, including proliferation, invasion and metastasis, in the human body. The orthotopic transplantation model of GC is stable, reliable and considered to be the most optimal model of GC so far. In the orthotopic transplantation mice with Znf139 knockdown, the growth of the tumor was evidently suppressed and there were signs of no lymphatic metastasis, suggesting that ZNF139 could affect the development and metastasis of GC tumors in vivo. In order to explore which genes are regulated by Znf139, changes of apoptosis-associated genes were detected in the cells and mice of each group. The Bcl-2 and survivin genes, the representative genes of the apoptotic pathway, were significantly downregulated following Znf139 knockdown, including their protein products. Previous studies found that Bcl-2 enhances the anti-apoptotic ability of the tumor cells by regulating the mitochondrial redox state of thiol (14). Survivin inhibits caspase activation, and therefore leads to the negative regulation of programmed cell death (15). In summary, these results show that the expression of anti-apoptotic associated genes, Bcl-2 and survivin, was extremely reduced following the silencing of Znf139. This indicates that ZNF139 could facilitate the growth and metastasis of GC by promoting Bcl-2 and survivin.

In the present study, ZNF139 was demonstrated to affect the growth and metastasis of GC tumors by inhibiting cell apoptosis. The establishment of a human GC nude mouse orthotopic transplantation model partly enabled the simulation of GC biological behavior the in human body. However, the anatomical structure and microcirculatory system are varied in the human body and nude mice, in addition to differences in the immunodeficiency of nude mice. Recent studies have shown that ZNF139 may be associated with multiple drug resistance by regulating the MDR1 and MRP1 genes (13). Therefore, future studies are recommended to focus on building animal models that are closer to the internal environment of the human body, as well as exploring the association between ZNF139, MDR1 and gene therapy in GC.